Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

First Phase 2 Trial in Sjögren's to Achieve the Primary Endpoint Both in Patients With Severe Symptomatology and Those  With Systemic Disease Results From Crossover Period Provide Further Evidence of the Clinical Efficacy and Safety of Dazodalibep in Sjögren's THOUSAND OAKS, Calif. , Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of Sjögren's.

AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023

Bank of America

Blackrock Inc

ConocoPhillips

Cisco Systems

Goldman Sachs

Johnson & Johnson

JPMorgan Chase & Co

Coca-Cola

MetLife

Altria

Morgan Stanley

NextEra Energy

PepsiCo

Pfizer

PNC Financial Services

Sempra Energy

Target

Texas Instruments

U.S. Bancorp

Vanguard High Dividend Yield ETF

There are 22 stocks on my high yield watchlist for November 2023. The majority of the stocks on my watchlist are undervalued based on dividend yield theory. An equally weighted portfolio of these stocks underperformed the Vanguard High Yield Dividend ETF by about 1% during the month of October.

High Yield Stock Watchlist - November 2023

Boeing

Salesforce

Chevron

Disney

Dow Inc

Merck

Verizon

Walgreens

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.”–Dow Jones & Co. The highest-yield 10 stocks are November's Dogs of the Dow: JNJ, AMGN, KO, GS, CVX, IBM, DOW, MMM, VZ, and WBA averaged a 5.02% annual yield. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated November net-gains ranged 19.78%-35.37%, topped by WBA 11/2/23.

November Dogs Of The Dow: 3 Buyable, 4 Watchable

Reykjavik, ICELAND , Nov. 6, 2023 /PRNewswire/ -- A comprehensive new study from deCODE genetics, a subsidiary of Amgen, published today in Nature Genetics, provides insights into the epidemiology and somatic and germline genetics of clonal hematopoiesis. Whole genome sequence data from Iceland and the UK Biobank, combined with a unique somatic mutation Barcoding strategy, was used to investigate clonal hematopoiesis at the population scale.

Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition

THOUSAND OAKS, Calif. , Nov. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data for KRYSTEXXA® (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment − uncontrolled gout − both with and without chronic kidney disease (CKD).

AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)

Microsoft

UnitedHealth Group

Walmart

The Dow Jones Industrial Average of blue chip stocks is trading higher for the week, but is still in correction territory, having posted losses in each of the past three months.

5 Dow stocks to track during the market correction

Breadth of Research Reflects Amgen's Commitment to Rheumatology Data Include Sjögren's Syndrome, Uncontrolled Gout, Severe Active ANCA-Associated Vasculitis and Psoriatic Arthritis THOUSAND OAKS, Calif. , Nov. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, following the recent acquisition of Horizon Therapeutics.

AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO

AbbVie

Bristol-Myers

Eli Lilly

Sanofi

The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector performance.

Investor patience tested as pharmaceutical stocks take a tumble

Amgen AMGN, -2.85% has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.

Amgen gets FDA approval for its inflammatory diseases treatment Wezlana

The U.S. Food and Drug Administration on Tuesday approved Amgen's biosimilar version of Johnson & Johnson's blockbuster psoriasis treatment Stelara for multiple inflammatory diseases.

U.S. FDA approves Amgen's biosimilar vesrion of J&J's Stelara

Amgen Inc. (NASDAQ:AMGN ) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman & CEO Murdo Gordon - EVP, Global Commercial Operations Vikram Karnani - Executive, Rare Disease Business David Reese - EVP, Research & Development Peter Griffith - CFO Conference Call Participants Michael Yee - Jefferies Yaron Werber - TD Cowen Terence Flynn - Morgan Stanley Salveen Richter - Goldman Sachs Jay Olson - Oppenheimer Umer Raffat - Evercore ISI Robyn Karnauskas - Truist Securities David Risinger - Leerink Partners Chris Raymond - Piper Sandler Mohit Bansal - Wells Fargo Gregory Renza - RBC Capital Markets Geoff Meacham - Bank of America Chris Schott - JPMorgan Evan Seigerman - BMO Tim Anderson - Wolfe Research Colin Bristow - UBS Operator My name is Julianne, and I'll be your conference facilitator today for Amgen's Third Quarter 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise.

Amgen Inc. (AMGN) Q3 2023 Earnings Call Transcript

Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.

Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View

Archer-Daniels-Midland Company

Advanced Micro Devices

Amazon

Deckers Outdoor

Halliburton

Lululemon Athletica

Matador Resources

Rexford Industrial Realty

T-Mobile US

Workday

Our list of the best stocks to buy now reflect the lesson of the past few years: Be ready for anything.

The 12 Best Stocks to Buy Now

Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Amgen (AMGN) Q3 Earnings

Amgen (AMGN) came out with quarterly earnings of $4.96 per share, beating the Zacks Consensus Estimate of $4.65 per share. This compares to earnings of $4.70 per share a year ago.

Amgen (AMGN) Q3 Earnings Top Estimates

Horizon Pharma

Amgen stock dipped Tuesday after the biotech company reported light sales for its biggest product. But the company boosted its outlook.

Amgen Boosts Outlook Following Horizon Takeover, But Dips On Light Enbrel Sales

In contrast to market expectations, shares of Amgen, Inc. (NASDAQ:AMGN) remained flat even as the biotechnology giant exceeded third-quarter earnings estimates and once again raised its financial guidance. For the three months ended September 30, the company reported a net income of $1.730 billion or $3.22 per share, down from $2.143 billion or $3.98 per share in the same quarter last year.

Amgen stock unmoved by earnings beat

The biotechnology company beat third-quarter adjusted earnings estimates but fell a bit short on sales.

Amgen Boosts Revenue Guidance. But the Stock Trades Lower.

Amgen Inc.'s stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again raised its guidance. The company posted net income of $1.730 billion, or $3.22 a share, for the quarter, down from $2.143 billion, or $3.98 a share, in the year-earlier period.

Amgen's stock jumps premarket after earnings beat and company again raises guidance

Amgen , which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.

Amgen third-quarter sales rise 5%; profit up before charge

THOUSAND OAKS, Calif. , Oct. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 20231.

AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS

bluebird bio

CRISPR Therapeutics

Editas Medicine

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The Food and Drug Administration will hold an advisory committee meeting for the first CRISPR/Cas9 gene-edited product candidate this week. If approved, CRISPR Therapeutics and Vertex Pharmaceuticals' sickle cell disease therapy could generate blockbuster sales figures.

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient

Dividend stocks haven't been top performers in 2023. Over lengthy holding periods, though, high-quality dividend stocks tend to deliver above-average returns.

2 Dow Jones Dividend Stocks to Buy Hand Over Fist Right Now

News for Amgen Stock (AMGN)